Norethisterone is bioconverted to oestrogenic compounds that activate both the oestrogen receptor α and oestrogen receptor β in vitro

European Journal of Pharmacology

Volumn 452, Issue 3, 2002, Pages 347-355

  Pasapera, Ana Maria ^a   Gutiérrez Sagal, Rubén ^a   Herrera, Joaquín ^a   Galicia Canales, Norma ^a   García de la Mora, Gustavo ^b   Ulloa Aguirre, Alfredo ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

19 Nor progestins; Norethisterone; Oestrogen receptor

Indexed keywords

3ALPHA,5ALPHA NORETHISTERONE; 3BETA,5ALPHA NORETHISTERONE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIGAND; NORETHISTERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REPORTER GENE;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; HUMANS; NORETHINDRONE; RECEPTORS, ESTROGEN; TRANS-ACTIVATION (GENETICS);

EID: 0037064233     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02337-3     Document Type: Article

References (48)

1. Blom M.J., Wassink M.G., van Wijk F., Ederveen A.G., Kloosterboer H.J., Verhoeven C.H., Lambert J.G., Goos H.J. Metabolism of norethisterone and norethisterone derivatives in rat uterus, vagina, and aorta. Drug Metab. Dispos. 29:2001;976-982.
2. Botella J., Duranti E., Viader V., Duc I., Delansorne R., Paris J. Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosterone derivatives on endometrial Ishikawa cells. J. Steroid Biochem. Mol. Biol. 55:1995;77-84.
3. Bowers A., Ringold H.J., Denot E. Steroid CI 19-nordihydrotestosterone derivates. J. Am. Chem. Soc. 80:1958;6115-6121.
4. Chávez B., Vilchis F., Pérez A.E., García G.A., Grillasca I., Pérez-Palacios G. Stereospecificity of the intracellular binding of norethisterone and its A-ring reduced metabolites. J. Steroid Biochem. 22:1985;121-126.
5. Chetyrkin S.V., Belyaeva O.V., Gough W.H., Kedishvili N.Y. Characterization of a novel type of human microsomal 3α-hydroxisteroid dehydrogenase. J. Biol. Chem. 276:2001;22278-22286.
6. Cowley S.M., Parker M.G. A comparison of transcriptional activation by ERα and ERβ J. Steroid Biochem. Mol. Biol. 69:1999;165-175.
7. Delaunay F., Pettersson K., Tujague M., Gustafsson J.A. Functional differences between the amino-terminal domains of estrogen receptors α and β Mol. Pharmacol. 58:2000;584-590.
8. Dijkema R., Schoonen W.G.E.J., Teuwen R., van der Struik E., de Ries R.J.H., van der Kar B.A.T., Olijve W. Human progesterone receptor A and B Isoforms in CHO cells: I. Stable transfection of receptor and receptor responsive genes: transcription modulation by antiprogestins. J. Steroid Biochem. Mol. Biol. 64:1998;147-156.
9. Eustice D.C., Feldman P.A., Colberg-Poley A.M., Buckery R.M., Neubauer R.H. A sensitive method for the detection of β-galactosidase in transfected mammalian cells. Biotechniques. 11:1991;739-742.
10. Giannoukos G., Szapary D., Smith C.L., Meeker J.E., Simons S.S. Jr. New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties. Mol. Endocrinol. 15:2001;255-270.
11. 4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. Mol. Endocrinol. 13:1999;66-81.
12. Gustafsson J.A., Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J. Steroid Biochem. Mol. Biol. 74:2000;245-248.
13. Jeng M.H., Parker C.J., Jordan V.C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res. 52:1992;6539-6546.
14. Jones P.S., Parrott E., White I.N. Activation of transcription by estrogen receptor α and β is cell type- and promoter-dependent. J. Biol. Chem. 274:1999;32008-32014.
15. Jordan C.V., Jeng M.H., Catherino B.S., Parker J.C. The estrogenic activity of synthetic progestins used in contraceptives. Cancer. 71:1993;1501-1505.
16. Kalkhoven E., Kwakkenbos-Isbrucker L., de Laat S.W., van der Saag P.T., van der Burg B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Mol. Cell Endocrinol. 102:1994;45-52.
17. Kemppainen J.A., Langley E., Choi-iok W., Bobseine K., Kelce W.R., Wilson E.M. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxiprogesterone acetate and dihydrotestosterone. Mol. Endocrinol. 13:1999;440-454.
18. Klein-Hitpass L., Schorpp M., Wagner U., Ryffel G.U. An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell. 46:1986;1053-1061.
19. Kuhnz W., Heuner A., Hümpel M., Seifert W., Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl-oestradiol in post-menopausal women. Contraception. 56:1997;379-385.
20. Kuihl H. Comparative pharmacology of newer progestagens. Drugs. 51:1996;188-215.
21. Kumar V., Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell. 55:1988;145-156.
22. Larrea F., Vilchis F., Chávez B., Pérez A.E., Garza-Flores J., Pérez-Palacios G. The metabolism of 19-nor contraceptive progestins modulates their biological activity at the neuroendocrine level. J. Steroid Biochem. 27:1987;657-663.
23. Larrea F., García-Becerra R., Lemus A.E., García G.A., Pérez-Palacios G., Jackson K.J., Coleman K.M., Dace R., Smith C.L., Cooney A.J. A-ring reduced metabolites of 19-nor-synthetic progestins as subtype selective agonists for ERα Endocrinology. 142:2001;3791-3799.
24. Lemus A.E., Vilchis F., Damsky R., Chavez B.A., Garcia G.A., Grillasca I., Pérez-Palacios G. Mechanism of action of levonorgestrel: in vitro metabolism and specific interactions with steroid receptors in target organs. J. Steroid Biochem. Mol. Biol. 41:1992;881-890.
25. Lemus A.E., Zaga V., Santillán R., García G.A., Grillasca I., Damián-Matzumura P., Jackson K.J., Cooney A.J., Larrea F., Pérez-Palacios G. The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. J. Endocrinol. 165:2000;693-702.
26. Lemus A.E., Santillán R., Damián-Matsumura P., García G.A., Grillasca I., Pérez-Palacios G. In vitro metabolism of Gestodene in target organs: formation of A-ring reduced derivatives with estrogenic activity. Eur. J. Pharmacol. 417:2001;249-256.
27. Markiewickcs L., Gurpide E. Estrogenic and progestagenic activities coexisting in steroidal drugs: quantitative evaluation by in vitro bioassays with human cells. J. Steroid Biochem. Mol. Biol. 48:1994;89-94.
28. Markiewicks L., Hochberg R.B., Gurpide E. Intrinsic estrogenicity of some progestagenic drugs. J. Steroid Biochem. Mol. Biol. 41:1992;53-58.
29. McKenna N.J., O'Malley B.W. From ligand to response: generating diversity in nuclear receptor coregulator function. J. Steroid Biochem. Mol. Biol. 74:2000;351-356.
30. Negro-Vilar A., Pérez-Palacios G. Reproduction, Growth and Development. 1991;175 Raven Press, New York.
31. Pace P., Taylor J., Suntharalingam S., Coombes R.C., Ali S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J. Biol. Chem. 272:1997;25832-25838.
32. Pasapera A.M., Camacho-Arroyo I., Savouret J.F., García G.A., Pérez-Palacios G., Pichon C., Cerbón M.A. In vitro molecular assessment of the mechanism of action of 19-nor progestins used as contragestational agents. Arch. Med. Res. 26:1995;S203-S207.
33. Pasapera A.M., Cerbón M.A., Castro I., Gutierrez R., Camacho A.I., García A.G., Pérez-Palacios G. Norethisterone metabolites modulate the uteroglobin and progesterone receptor gene expression in prepubertal rabbits. Biol. Reprod. 52:1995;426-432.
34. Pasapera A.M., Gutiérrez-Sagal R., García-Becerra R., Ulloa-Aguirre A., Savouret J.F. Transactivation of estrogen and progestin responsive promoters by 19-Nor progestins in African Green Monkey Kidney CV1 cells. Endocrine. 16:2001;217-225.
35. Pérez-Palacios G., Cerbón M.A., Paspera A.M., Castro I., Enríquez J., Vilchis F., García G.A., Moralí G., Lemus A.E. Mechanisms of hormonal and antihormonal action of contraceptive progestins at the molecular level. J. Steroid Biochem. Mol. Biol. 41:1992;479-486.
36. Pothier F., Ouellet M., Julien J.P., Guerin S.L. An improved CAT assay for promoter analysis in either transgenic mice or tissue culture cells. DNA Cell. Biol. 11:1992;83-90.
37. Rabe T., Bohlman M.K., Rehberger-Shneider S., Prifu S. Induction of estrogen receptor-α and -β activities by synthetic progestins. Gynecol. Endocrinol. 14:2000;118-126.
38. Ravinder P., Shatrugna V., Madhavan N., Sivakumar B. Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women. Contraception. 5:1997;373-379.
39. Rebar R.W., Zeserson K. Characteristics of the new progestagens in combination oral contraceptives. Contraception. 44:1991;1-10.
40. Savouret J.-F., Fridlanski F., Atger M., Misrahi M., Berger R., Milgrom E. Origin of the high constitutive level of progesterone receptor in T47-D breast cancer cells. Mol. Cell. Endocrinol. 75:1991;157-162.
41. Schoonen W.G.E.J., Joosten W.H., Kloosterboer H.J. Effects of two classes of progestagens, pregnane and 19-nor-testosterone derivatives, on cell growth of human breast tumor cells: II. T47-D cell lines. J. Steroid Biochem. Mol. Biol. 55:1995;439-444.
42. Schoonen W.G.E.J., Dijkema R., Ries R.J.H., Wagenaars J.L., Joosten J.W.H., Gooyer M.E., Deckers G., Kloosterboer H.J. Human progesterone receptor A and B isoforms in CHO cells: II. Comparison of binding, transactivation and ED50 values of several (Anti) progestagens in vitro in CHO and MCF-7 cells and in vivo in rabbits and rats. J. Steroid Biochem. Mol. Biol. 64:1998;157-170.
43. Schoonen W.G.E.J., Deckers G., Gooijer M.E., Ries R., Kloosterboer H.J. Hormonal properties of norethisterone, 7α-methyl-norethisterone and their derivatives. J. Steroid Biochem. Mol. Biol. 74:2000;213-222.
44. Short R.V. Ovarian steroid synthesis and secretion in vivo. Rec. Prog. Horm. Res. 20:1964;303-340.
45. Stiruk-Ware R. Progestins in menopause. J. Steroid Biochem. Mol. Biol. 69:1999;185-193.
46. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 59:1989;477-487.
47. Vilchis F., Chávez B., Pérez A.E., García G.A., Angeles A., Pérez-Palacios G. Evidence that a non-aromatizable metabolite of norethisterone induces estrogen-dependent pituitary progesterone receptors. J. Steroid Biochem. 24:1986;525-531.
48. Zambrano E., Zariñán T., Olivares A., Barrios-de-Tomasi J., Ulloa-Aguirre A. Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems. Implications for the structure-function relationship of the FSH variants. Endocrine. 10:1999;113-121.